Prudentia Sciences is an AI-powered technology platform focused on accelerating investment in breakthrough therapies that change the world.

Prudentia’s AI-powered technology accelerates investment in breakthrough therapies. Their mission is to empower biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact. They aim to enable investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking, and equip investors with data-driven insights to optimize capital allocation in drug asset transactions.

Prudentia offers real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms, enabling speed to decision with increased deal throughput. Their AI-powered synthesis of datarooms into asset assessment frameworks enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers. They provide AI-guided product profiles and asset valuations to guide portfolio strategy and decision making, along with concise and prioritized reviews of risks and opportunities for drug asset staging.

The platform is designed for Pharma, Biotech, and Investors with tailored benefits for CEOs, CFOs, Research and Development, Business Development and Licensing teams, Scientific Founders, Business Development Leads, venture capital, private equity, and hedge funds.